CELL SIGNALING TECHNOLOGY search Cell Signaling Technology ERBB2 products
includes other brands or spellings
|
| wb | | Cell Signaling Technology rabbit polyclonal anti-HER-2/ErbB2 antibody was used in western blot to study expression of p53, ErbB1, ErbB2, and Raf-1 in lung cancer. |
SIGMA-ALDRICH search Sigma-Aldrich ERBB2 products
includes other brands or spellings
|
| ih | | Sigma ERBB2 antibody was tested in immunohistochemistry by Human Protein Atlas. |
SANTA CRUZ BIOTECHNOLOGY search Santa Cruz Biotechnology ERBB2 products
includes other brands or spellings
|
| ic, ip, wb | | Santa Cruz Biotechnology anti-erbB2 antibody was used in immunocytochemistry, western blot and immunoprecipitation to study that neuregulin-1 enhances motility and migration of human astrocytic glioma cells. |
| ip, wb | | Santa Cruz Biotechnology anti-ErbB-2 antibody was used in western blot and immunoprecipitation to study that extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. |
| wb | | Santa Cruz Biotechnology anti- ErbB2 (C-17) was used in western blot to examine ErbB2 expression levels in human bladder cancer cell lines 5637 and T24, T-47D breast cancer cells, Wild-type NIH 3T3 clone 7 mouse fibroblasts, as well as NIH 3T3 clone 7 fibroblasts overexpressing ErbB1, ErbB2, ErbB3, or ErbB4. |
| wb | | Santa Cruz Neu atibody was used in western blot to study the role of DecR1 in mammary tumor development. |
BD BIOSCIENCES search BD Biosciences ERBB2 products
includes other brands or spellings
|
| wb | | BD Transduction erbB2 antibody was tested in western blot by Abminer. |
EMD BIOSCIENCES search EMD Biosciences ERBB2 products
includes other brands or spellings
|
| elisa | | Oncogene Science HER-2 sandwich enzyme-linked immunosorbent assay kit was used to measure serum HER-2 concentration. |
| ip | | Oncogene Research HER-2 mAb (Ab-3) was used in western blot and immunoprecipitation to study HER-2 down-regulation in colon cancer cells. |
| wb | | Oncogene Research Products HER2 antibody was used in western blot to study gene regulation by anti-HER2 antibody. |
| wb | | Calbiochem anti-Her2 Ab3 antibody was used in western blot and immunoprecipitation to identify LRIG1 as a novel negative regulator of the Met receptor and its role on opposing Met and Her2 synergy. |
| wb | | Calbiochem ErbB2 antibody was used in western blot to study the expression and role of Nrdp1 in cancer. |
MILLIPORE search Millipore ERBB2 products
includes other brands or spellings
|
| wb | | Upstate Biotechnology polyclonal HER-2 and phospho-HER-2 antibodies were used in western blot to study the inhibition EGFR family members in colon and breast cancer cells. |
THERMO FISHER SCIENTIFIC search Thermo Fisher Scientific ERBB2 products
includes other brands or spellings
|
| ic, wb | | Lab Vision four monoclonal ErbB2 antibodies, clone 9G6.10 and L87 + e2–4001 (against the extracellular domain), clone e2–4001 + 3B5, and NeoMarkers 1 (against the phosphorylated tyrosine 1248) were used in western blot and immunocytochemistry to study ErbB2 translocation in polarized epithelial cells. |
| ip, wb | | Neomarkers anti-HER2 monoclonal antibody was used in western blot and immunoprecipitation to study estrogen receptor alpha in breast cancer cells. |
| wb | | Lab Vision c-erbB-2/HER-2/neu Oncoprotein Ab-8 antibody was tested in western blot by Abminer. |
BECKMAN COULTER search Beckman Coulter ERBB2 products
includes other brands or spellings
|
| ic | | DakoCytomation polyclonal ErbB2 antibody was used in immunocytochemistry to study ErbB2 translocation in polarized epithelial cells. |
| ih | | AKO rabbit polyclonal anti-HER2/neu (anti-c-erbB-2) antibody was used in immunohistochemistry o study HER2/neu overexpression in breast cancer patients. |
| ih | | DakoCytomation ERBB2 antibody was tested in immunohistochemistry by HPA (HPA001383) . |
| ih | | DAKO anti-Her2/neu antibody was used in immunohistochemistry to study expression of cytokeratin 17 and/or cytokeratin 5/6 in tumor cells. |
| ih | | DAKO rabbit polyclonal antibody for human epidermal growth factor receptor 2 (HER2; clone A0485) was used in immunohistochemistry to study the biological significance of estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. |
| ih | | DAKO anti-HER2 polyclonal antibody was used in immunohistochemistry to study the tissue microarray validation of Epidermal Growth Factor Receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. |
| ih | | Dako rabbit polyclonal anti-HER2/neu protein antibody (clone Mib-1) was used in paraffin sections from human cancer and in immunohistochemistry to study the effect of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. |
| ih | | Dako polyclonal anti-HER-2/neu antibody was used in immunohistochemistry to detect HER-2/neu in adjacent serial sections of two breast invasive ductal carcinomas from patients. |
DAKO NORTH AMERICA
|
| ih | | Dako North America anti-Her2neu antibody (CB11) was used in paraffin sections from human breast cancer and in immunohistochemistry to study the role for IL-6 in driving Stat3 activation in breast cancer. |
GENENTECH
|
| block | | Genentech anti-HER2 murine monoclonal antibody 4D5 and humanized monoclonal antibody trastuzumab (Herceptin) were used in blocking expriments to study gene regulation by anti-HER2 antibody. |
| ic | | Genentech anti-ErbB2 antibody 3E8 was used in immunocytochemistry to identify the leucine-rich repeat protein LRIG1 as a negative regulator of ErbB family receptor tyrosine kinases. |
NICHIREI
|
| ih, wb | | Nichirei rabbit anti-c-erbB-2 polyclonal antibody was used in western blot and immunohistochemistry to study the frequent co-Localization of cox-2 and laminin-5 2 chain at the invasive front of early-stage lung adenocarcinomas. |
NOVOCASTRA
|
| ih | | Novocastra CB11 HER2 antibody was used in immunohistochemistry to study ovarian cancers in BRCA1 and BRCA2 carriers. |
| ih | | NovoCastra anti-HER2/neu antibody CB11 was used in immunohistochemistry to study the association of α-Methylacyl-CoA racemase protein expression with the degree of differentiation in breast cancer. |
| ih | | Novocastra monoclonal anti-HER-2/neu antibody was used in immunohistochemistry to detect HER-2/neu in adjacent serial sections of two breast invasive ductal carcinomas from patients. |
| ih | | Novocastra monoclonal anti-ErbB2 antibody (NCL-CB11) was used in immunohistochemistry to detect the localization of ErbB2 in human transitional cell carcinoma (TCC) of the urinary bladder and histologically normal regions of urinary bladders from patients with prostate cancer, as well as in clone 7 mouse NIH 3T3 cells as positive and negative controls. |
| ih | | NovoCastra anti-c-erbB2 antibody (clone CB11) was used in tissue sections from human and in immunohistochemistry to study the cell cycle regulation in patients with IM at the GOJ. |
| ih | | NovoCastra monoclonal anti-c-erbB-2 antibody was used in immunohistochemistry to study CD1d and invariant NKT cells at the human maternal-fetal interface. |
VENTANA MEDICAL SYSTEMS
|
| ih | | Ventana Medical Systems rabbit polyclonal anti-HER-2 antibody was used in paraffin sections from human breast cancer and in immunohistochemistry to study the role of 17ß-estradiol for down-regulation of Cap43/NDRG1/Drg-1 in human breast cancer cells. |
Articles Reviewed |
| 1. Toshiro Niki et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. 2002 |
| 2. Xiaodan Yu et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. 2002 |
| 3. Jonathan E Boyson et al. CD1d and invariant NKT cells at the human maternal-fetal interface. 2002 |
| 4. Matt van de Rijn et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. 2002 |
| 5. Tiho Miralem et al. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. 2003 |
| 6. Patricia A Ritch et al. Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. 2003 |
| 7. Victoria P Ramsauer et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. 2003 |
| 8. Andrea Decensi et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. 2003 |
| 9. Torsten O Nielsen et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. 2003 |
| 10. Teemu T Junttila et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. 2003 |
| 11. N J Trudgill et al. Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. 2003 |
| 12. Sunil R Lakhani et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. 2004 |
| 13. Zhibo Yang et al. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. 2004 |
| 14. Weiya Xia et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. 2004 |
| 15. Takashi Suzuki et al. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. 2004 |
| 16. Melanie B Laederich et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. 2004 |
| 17. Majida Esslimani-Sahla et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. 2004 |
| 18. Vanesa Gregorc et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. 2004 |
| 19. Xiao-Feng Le et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. 2005 |
| 20. Scott K Kuwada et al. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. 2005 |
| 21. Hu Xu et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. 2005 |
| 22. Agnieszka K Witkiewicz et al. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. 2005 |
| 23. Sylvia M Major et al. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. 2006 |
| 24. Abbas Fotovati et al. 17Beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells. 2006 |
| 25. Anja Persson et al. A human protein atlas based on antibody proteomics. 2006 |
| 26. Lily Yen et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. 2006 |
| 27. David L Shattuck et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. 2007 |
| 28. Marjan Berishaj et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. 2007 |
| 29. Josie Ursini-Siegel et al. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. 2007 |